THE first major London solo exhibition by critically acclaimed Indian artist Shilpa Gupta has premiered in the capital this month.
Held at the Barbican Centre, Gupta’s Sun at Night presents and builds on her acclaimed project For, In Your Tongue, I Cannot Fit (2017–18).
It is an immersive multi-channel installation which comprises 100 microphones suspended above 100 metal spikes, each piercing a page inscribed with a fragmented verse of poetry by a poet incarcerated for their work, writings, or beliefs.
It is described as giving a voice to those who had been silenced, highlighting the “fragility and vulnerability of one’s right to personal expression whilst raising urgent questions of free expression, censorship, confinement, and resistance.”
An installation view of Shilpa Gupta's exhibition Sun at Night
The installation’s commentary on censorship is “unfortunately as relevant as ever”, Gupta said. She believes the space for speaking freely has continued to shrink. “We are living in times where larger structures have the ability to pry into personal spaces which they do not hold back from intruding into,” the artist told Eastern Eye.
For, In Your Tongue, I Cannot Fit, is linked to one of Gupta’s early exhibitions Someone Else (2011). It is an installation of 100 books written anonymously or under pseudonyms, based on writers who wrote under a fictitious name. This was to seek freedom in being ‘someone else’ –whether to conceal their gender, avoid personal or political persecution, or even to publish a rejected work.
Gupta’s work often explores themes of identity, nation borders and censorship. Her Blame (2002) performance project saw her peddle small bottles of fake blood in Mumbai local trains with a label that reads: “Blaming you makes me feel so good, so I blame you for what you cannot control, your religion, your nationality.”
The work was conceived shortly after several instances of major conflict, such as the 9/11 terrorist attacks and the 2002 Gujarat riots.
Shilpa Gupta's Blame performance project saw her peddle small bottles of fake blood in Mumbai
The intrigue derives from the “inter-relationships between large structures and individuals”, Gupta revealed, “when systems, be it the state, or even otherwise, attempt to map, graph, tabulate to seek control, people masquerade, infiltrate, and catapult”.
“The works are about the persistence of beliefs, dreams, mobility, which make us, what we are, as individuals.”
While putting together Someone Else, Gupta found that a number of notable writers resorted to using fake names. This included 1984 author George Orwell, whose birthname was Eric Arthur Blair. It is reported he used a pen name prior to the publication of his first novel, Down and Out in Paris and London, so his family would not be embarrassed by his time in poverty.
Even one of Gupta’s favourite writers, the Indian author Premchand, had taken a fake name. Regarded as one of the greatest Indian writers of the early 20th century, he assumed the pen name Nawab Rai for his first novel, Mystery of God’s Abode.
It came to Gupta’s attention that Premchand’s books were once burnt and he had been charged with sedition (promoting rebellion against the government, through speech or writing.)
For, In Your Tongue, I Cannot Fit, is linked to one of Gupta’s early exhibitions Someone Else (pictured).
“As usual, questions lead to some answers, and then more questions. I started looking at the moments when the mobility of words caused such discomfort to those who sought to restrict imagination through the mobility of a writer,” Gupta said. “This, along with the changing atmosphere under the current government in India, which has been turning restrictive, led me to becoming interested in the power of words, and the nervousness around them felt by those in power.”
Showcasing her first solo exhibition in London is a special moment for Gupta, who has only exhibited group shows in the capital previously. “It is wonderful to be able to show a project at a public multidisciplinary venue like the Barbican,” she said.
Outside of London, she has participated in the Liverpool Biennale and Manchester Asian Art Triennale and had a solo show at Bristol’s Arnolfini art centre. Gupta’s work has been shown at spaces all over the world including the Netherlands, Germany, and the United States.
Shilpa Gupta
She said her 2006 show at the Havana Biennale in Cuba was a highlight. The festival is the largest visual arts event in the country.
“It was a particularly memorable experience as, despite limited resources, a magnificent show was mounted in which artists from all over came together with a wonderful sense of warmth and generosity,” she recalled. “It was also a place where I received overwhelming moving responses to my works from general audiences which gives one strength and a sense of belief in the possibilities of art.”
Shilpa Gupta: Sun at Night will be exhibited at The Curve, Barbican Centre, until February 6 2022
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.